Z-1991-2019Class II

Apolipoprotein A1 is an in vitro diagnostic assay for the quantitative determination of apolipoprotein A1 in...

Name: Z-1991-2019 Apolipoprotein A1 is an in vitro diagnostic assay for the quantitative determination of apolipoprotein A1 in...
Creator: Abbott Laboratories, Inc
Published: 2018-05-16
License: https://open.fda.gov/license/

Abbott Medical / initiated 2018-05-16 / Terminated / root cause: labeling and UDI

FDA source

Abbott Laboratories, Inc began a recall of Apolipoprotein A1 is an in vitro diagnostic assay for the quantitative determination of apolipoprotein A1 in human serum or plasma. Antibodies to... on 2018-05-16. FDA classified it as Class II and gives the reason as "An update to the Reagents and Specimen Collection and Handling/Preparation for Analysis sections of the IFU was required due to different issues with the various products". As of 2026-09-10, the recall status on record is Terminated, and MDM tags the root cause as labeling and UDI.

Recall record

Recall number: Z-1991-2019
Classification: Class II
Status: Terminated
Initiated: 2018-05-16
Posted: 2019-07-19
Terminated: 2021-08-16
Recalling firm: Abbott Medical
Product: Apolipoprotein A1 is an in vitro diagnostic assay for the quantitative determination of apolipoprotein A1 in human serum or plasma. Antibodies to apolipoprotein A1 combine with apolipoprotein A1 in the sample to form insoluble immune complexes. The immune complexes cause an increase in light scattering (turbidity). The resulting increase in sample turbidity, measured at 804 nm, is directly proportional to the concentration of apolipoprotein A1 in the sample.
Product code: DER Alpha-1-Lipoprotein, Antigen, Antiserum, Control
Reason for recall: An update to the Reagents and Specimen Collection and Handling/Preparation for Analysis sections of the IFU was required due to different issues with the various products.
Root cause tag: labeling and UDI
FDA root cause: Under Investigation by firm
Action: The recalling firm issued letters dated 5/16/2019 via FedEx priority overnight express on 5/16/2019 to the U.S. customers. For OUS, each country organization needs to establish their own method of notification, which normally consists of mailings or customer visits.
Quantity in commerce: 2,112 kits
Distribution: Distribution was nationwide, including Puerto Rico. There was government/military distribution. Foreign distribution was made to Canada, Albania, Algeria, Andorra, Argentina, Armenia, Australia, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Bolivia, Bosnia and Herzegovi, Botswana, Brazil, Brunei, Bulgaria, Chile, China, Costa Rica, Croatia, Curacao (Netherlands Antilles), Cyprus, Czech Republic, Democratic Republic of the Congo, Denmark, Ecuador, Egypt, Estonia, Finland, France, Gaza & Jericho, Germany, Greece, Greenland, Honduras, Hong Kong, India, Iraq, Ireland, Israel, Italy, Ivory Coast, Jamaica, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Latvia, Lebanon, Libya. Lithuania, Luxembourg, Macedonia, Malaysia, Maldives, Mali, Mauritania, Mexico, Moldova, Montenegro, Morocco, Namibia, Netherlands, New Zealand, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Republic of Yemen, Romania, Russia, Rwanda, Saudi Arabia, Senegal, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Tanzania, Thailand, Trinidad & Tobago, Tunisia, Turkey, Turks and Caicos, Tunisia, UAE, United Kingdom, Uruguay, and Viet Nam.
Product codes and lots: All IFU's

Enforcement reports

One row per recalled product line

FDA enforcement reports joined to recall event Z-1991-2019
Recall number	Class	Status	Voluntary or mandated	Report date	Classified
Z-1987-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1988-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1989-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1990-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1991-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1992-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1993-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1994-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19
Z-1995-2019	Class II	Terminated	Voluntary: Firm initiated	2019-07-31	2019-07-19

Product code DER

K983289Class IIApolipoprotein A1Abbott Laboratories / cleared 1999-01-29

MDM coverage of this record lists here, newest first.

About this record

Sourced from the FDA device recall database and the FDA enforcement reports, both ingested from openFDA. The recall record supplies the product, the reason and the product code; the enforcement report supplies the classification. The two datasets are exported by FDA on different days, and the date above is the older of the two, so nothing on this page is newer than it says.

MDM adds the root cause tag, derived from FDA’s own root cause text, and the cross-links to the product code, the clearances named on the record and MDM coverage. Where a recall has not been joined to an enforcement report, no classification is shown.

Data as of 2026-09-30, the FDA export date for this dataset. Page last changed 2026-09-05. View this recall on fda.gov (opens on fda.gov)